TB006 for Autism Spectrum Disorder
NCT06500637
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Multisite 14-week prospective double-blind placebo controlled parallel-group randomized clinical trial with 14-week open-label extension at the end of double-blind treatment phase for placebo subjects. Eligible subjects will be randomized within each site in 2:1 ratio to receive either TB006 or placebo treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Autism Spectrum Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 35 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Rossignol Medical Center
- Last updated on ClinicalTrials.gov
- April 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Rossignol Medical Center · Phoenix, AZ
California · 1
- Rossignol Medical Center · Aliso Viejo, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.